Clincosm LogoSign in Get a demo

Refractory Follicular Lymphoma

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, Refractory Follicular Lymphoma Trial (Tazverik (Tazemetostat))

Not yet recruiting
  • Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Tazverik (Tazemetostat)
  • (no location specified)
Oct 6, 2023

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Aberdeen, United Kingdom
  • +24 more
Apr 28, 2023

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine

Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +13 more
  • Anchorage, Alaska
  • +422 more
Feb 2, 2023

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Boston (TAZEMETOSTAT, Zandelisib)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Boston, Massachusetts
  • +1 more
Oct 28, 2022

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)

Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 26, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

Recruiting
  • Anaplastic Large Cell Lymphoma
  • +19 more
  • Duarte, California
  • +2 more
Aug 15, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Worldwide (Loncastuximab Tesirine, Idelalisib)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Las Vegas, Nevada
  • +33 more
Jul 26, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

Not yet recruiting
  • Post-Transplant Lymphoproliferative Disorder
  • +10 more
  • Loncastuximab Tesirine
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2022

Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
Jul 6, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United

Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
May 10, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)

Completed
  • Mantle Cell Lymphoma
  • +6 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 18, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +11 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 29, 2021